Phase 2 N=137 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate — 74.5 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=170 Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention
Taking Benzodiazepines for Any Reason for 3 Months · Benzodiazepine Dependence
Primary: 25% Reduction in Benzodiazepine Use — 14; 6 Participants
Phase 3 N=120 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain
Neonatal Abstinence Syndrome
Primary: Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) — 0.5; 0.3; 1.0; 0.6 score on a scale
N/A N=114 Comparing Clinical Outcomes Using Two Insole Manufacture Techniques
Foot Injury · Foot Deformity · Foot Sprain
Primary: Foot Health Status Questionnaire (FHSQ) - Pain Sub-domain — 78.13; 78.75; 72.50; 78.13 units on a scale
Phase 2 N=53 Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
Postural Orthostatic Tachycardia Syndrome
Primary: Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version) — -14.369; -15.957 score on a scale
N/A N=20 Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients
Pseudophakia
Primary: Binocular Best Corrected Distance Visual Acuity — -0.05 logMAR
N/A N=5 Brasthesis Prosthetic Harness for Women Veterans With Upper Limb Amputations
Upper Limb Amputation
Primary: Change in Prosthetic Function and Satisfaction Using the Orthotic and Prosthetic Users Survey (OPUS) — 73 Units on a scale
Phase 3 N=2,499 Secondary Prevention of Cardiovascular Disease in the Elderly Trial
Myocardial Infarction · Cardiovascular Disease
Primary: Major Cardiovascular Adverse Events (MACE) — 156; 118 number of adjudicated events — p=< 0.025
N/A N=2,484 Randomized Controlled Trial to Address Unintended Pregnancy Rates in Low Resource Settings
Contraceptive Usage · Unintended Pregnancy
Primary: Percentage Change in Current Modern Contraceptive Use — -1.1; 1.4; 1.5 percentage of participants
Phase 3 N=308 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Squamous Cell Carcinoma of the Anal Canal
Primary: Progression-free Survival (PFS) — 9.3; 7.4 months — p=0.0006
Phase 2 N=18 Trial of NanoPac Intratumoral Injection in Lung Cancer
Lung Cancer, Nonsmall Cell · Lung Cancer · Lung Cancer, Small Cell
Primary: Number of Participants With Treatment Emergent Adverse Events — 18 Participants
Phase 1 N=20 A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
Anemia, Sickle Cell
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 0; 0; 0; 0 Participants
Phase 4 N=1,025 Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron
Iron Deficiency Anemia (IDA)
Primary: Multidimensional Assessment of Fatigue (MAF) Scores — -8.8; -8.1 units on a scale
N/A N=59 Intervening in Food Insecurity to Reduce and Mitigate (InFoRM) Childhood Obesity
Pediatric Obesity · Nutrition Disorders · Overnutrition, Child
Primary: Study Feasibility: Recruitment — 59; 10 Participants
Phase 4 N=15 Healing Ointment Usage Post-surgical Procedure
Surgical Wound
Primary: Objective Erythema Assessment Using Clinical Grading Analog Scale — 0.8; 0.83; 0.75; 0.29 score on a scale